We found that there are differences in the expression of APOBEC1/3A/3G/3H across cancers, and may play different roles in different cancers; however, the high expression and amplification variation of APOBEC1/3A/3G/3H are significantly related to worse clinicopathological features and prognosis of PAAD patients. Here, APOBEC1 is linked to cancer.